ST-Segment-Elevation Myocardial Infarction During COVID-19 Pandemic Insights From a Regional Public Service Healthcare Hub
ST-Segment-Elevation Myocardial Infarction During COVID-19 Pandemic Insights From a Regional Public Service Healthcare Hub
复制标题
DOI：
10.1161/circinterventions.120.009413
复制
发表时间：
2020-08-01
影响因子：
5.6
通讯作者：
Cappelletti, Alberto Maria
中科院分区：
文献类型：
--
作者：
Gramegna, Mario;Baldetti, Luca;Cappelletti, Alberto Maria
背景：2019冠状病毒病（COVID-19）大流行导致社会、经济和医疗保健网络发生快速而彻底的转变。因此，COVID-19爆发可能对ST段抬高型心肌梗死（STEMI）患者的临床表现和管理产生深远的间接影响。本研究旨在评估COVID-19大流行期间STEMI患者的临床特征。研究方法：这项来自米兰地区公共服务医疗中心的单中心前瞻性研究纳入了2020年2月21日至4月1日（COVID-19大流行期间）入住我们研究所的所有连续STEMI患者。将这些患者与2018年和2019年类似时间段（2月21日至4月1日）因STEMI入院的历史患者队列进行比较，包括从症状发作到入院的时间、临床特征和住院结局。结果如下：在研究期间，共有26名患者因STEMI入院，其中7名（26.9%）患者的严重急性呼吸综合征冠状病毒2检测呈阳性。入院时，药物治疗，包括血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的使用，队列之间相似。与历史队列相比，2020年从症状发作到入院的中位（四分位距）时间显著延长（15.0 [2.0-48.0] vs 2.0 [1.0-3.0]小时;P
Background: Coronavirus disease 2019 (COVID-19) pandemic has led to a fast and radical transformation in social, economic, and healthcare networks. COVID-19 outbreak may thus have profound indirect consequences on clinical presentation and management of patients with ST-segment-elevation myocardial infarction (STEMI). Aim of this study was to assess clinical features of patients with STEMI during COVID-19 pandemic. Methods: This single-center, prospective study from a regional public service healthcare hub in Milan included all consecutive patients with STEMI admitted to our institute from February 21 to April 1, 2020 (during COVID-19 pandemic). These patients were compared with a historical cohort of patients admitted for STEMI during the analogous time period (February 21 to April 1) in 2018 and 2019, in terms of time from symptoms onset to hospital admission, clinical characteristics, and in-hospital outcomes. Results: A total of 26 patients were admitted for STEMI during the study period, and 7 (26.9%) of these patients tested positive for severe acute respiratory syndrome coronavirus 2. On admission, medical therapy, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers use, was similar between cohorts. Median (interquartile range) time from symptoms onset to hospital admission was significantly longer in 2020 as compared to the historical cohort (15.0 [2.0-48.0] versus 2.0 [1.0-3.0] hours;P